View printer-friendly version
« Back
March 02, 2004 5:00 p.m.
Teva Comments On Biovail Arbitration Claim
Jerusalem, Israel, March 2, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its subsidiary has received notification from Biovail Laboratories Incorporated, a subsidiary of Biovail Corporation International, that it has initiated an arbitration proceeding in connection with a dispute regarding payments made to Biovail under the companies' 1997 agreement. Biovail claims damages for alleged under-reporting of net sales under the 1997 agreement and also seeks to terminate the agreement with Teva's subsidiary as a result of what it characterizes as a material contractual breach in the agreement between the two companies. The arbitration demand also includes a RICO claim.

Teva categorically denies the allegations and looks forward to resolving the dispute in arbitration.

Teva's Chief Executive Officer, Mr. Israel Makov commented: "We believe that Biovail's claims are based on inaccurate assertions and incorrect conclusions and reflect a basic misinterpretation of the contract and our conduct under it. We look forward to resolving what we regard, at best, as a disagreement in the normal course of our business relationship, one that has yielded a great deal of success for both companies during the last several years. Therefore, we totally disagree with Biovail's aggressive litigation position."

During the arbitration, according to the contract, the contract will continue to remain in full force and effect and Teva will continue to order products from Biovail for supply to customers. Any notice of termination for a material breach cannot be served until after the arbitration panel has ruled and the cure period has lapsed.

In December 1997, Teva's subsidiary and Biovail Laboratories Incorporated entered into a marketing and distribution agreement which provided Teva with exclusive U.S. marketing rights for Biovail's pipeline of eight controlled-release generic versions of successful brands. These products include generic versions of Cardizem®CD, Adalat®CC, Procardia XL®, and Voltaren®XR.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 30 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.



Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration ("FDA") and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Company Contacts:

Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
(011) 972-2-589-2840

Bill Fletcher
President and CEO
Teva North America
(215) 591-8800

Dorit Meltzer
Director, Investor Relations
Teva Pharmaceutical Industries Ltd.
(011) 972-3-926-7554